• Mineralys Therapeutics to Participate in Three Upcoming Conferences

    Source: Nasdaq GlobeNewswire / 09 Nov 2023 16:05:00   America/New_York

    RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London on November 14-16, and the Evercore ISI 6th Annual HealthCONx Conference being held in Miami on November 28-30.

    Stifel Healthcare Conference:
    Date: Wednesday, November 15, 2023
    Time: 12:40pm EST
    Format:Fireside Chat
      
    Jefferies London Healthcare Conference:
    Date: Thursday, November 16, 2023
    Time:10:30am GMT
    Format:Corporate Presentation
    Webcast:Link
      
    Evercore ISI 6th Annual HealthCONx Conference:
    Date: Wednesday, November 29, 2023
    Time: 11:15am EST
    Format:Fireside Chat
    Webcast:Link

    A live webcast of the presentation and fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcasts will be available on the Company’s website for approximately 90 days.

    About Mineralys Therapeutics
    Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

    Contact:
    Investor Relations
    investorrelations@mineralystx.com

    Media Relations
    Tom Weible
    Elixir Health Public Relations
    Phone: (1) 515-707-9678
    Email: tweible@elixirhealthpr.com


    Primary Logo

Share on,